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Mutations in leucine-rich repeat kinase 2 (LRRK2) cause inherited
Parkinson disease (PD), and common variants around LRRK2 are
a risk factor for sporadic PD. Using protein–protein interaction arrays,
we identified BCL2-associated athanogene 5, Rab7L1 (RAB7, member
RAS oncogene family-like 1), and Cyclin-G–associated kinase as bind-
ing partners of LRRK2. The latter two genes are candidate genes for
risk for sporadic PD identified by genome-wide association studies.
These proteins form a complex that promotes clearance of Golgi-
derived vesicles through the autophagy–lysosome system both
in vitro and in vivo. We propose that three different genes for
PD have a common biological function. More generally, data in-
tegration from multiple unbiased screens can provide insight into
human disease mechanisms.
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Genetics contribute to the pathogenesis of Parkinson disease(PD) in two ways. Mutations in several genes can cause
inherited PD (1), and risk factor variants contribute to the risk of
sporadic PD (2). Some genes contribute to both mechanisms.
These pleomorphic risk loci (3) include genes that encode
α-synuclein and leucine-rich repeat kinase 2 (LRRK2) (4).
However, risk factors for sporadic PD identified by genome-
wide association studies (GWASs) (5–9) actually nominate large
genomic loci with multiple candidate genes (10). These loci may
include variants that change amino acids or affect disease risk
through gene expression (11). Also, whether all of the genes for
PD converge on a small number of biological pathways is unknown
(1). It is, therefore, important to develop unbiased approaches
that would resolve whether genes for PD have similar biological
functions and understand the mechanism(s) of disease risk.
Here, we examine one genetic cause of PD (LRRK2) and show
that identifying protein interaction partners can clarify disease
mechanisms.
Results
LRRK2 contains several protein–protein interaction motifs (shown
diagrammatically in Fig. 1A). To identify protein interactions, we
probed protein–protein arrays with biotinylated Glutathione-S
transferase (GST)-LRRK2970–2527, which was kinase-active and
therefore, likely folded (SI Appendix, Fig. S1). Biotinylated GST
was used as a negative control to exclude false positives that might
nonspecifically bind to many proteins. We also included arrays
where LRRK2 was coincubated with GDP or GMPPcP. These
experiments recovered several candidate interactors, including
three members of the Bcl2-associated athanogene (BAG) do-
main cochaperones (12) (SI Appendix, Table S1 and Datasets S1
and S2). Of these candidates, we chose to focus on BAG5, be-
cause it is expressed in neurons and enhances dopaminergic
neuronal death (13).
Some known interactors of LRRK2, such as 14-3-3 proteins
(14, 15), could not have been recovered with the truncated
LRRK2 probe that lacks the S910/S935 14-3-3 binding sites.
Therefore, we repeated the experiments with full-length Flag-
tagged LRRK2 (16) with Flag-tagged green fluorescent protein
(GFP) as a negative control. We confirmed interaction with the
BAG cochaperones (SI Appendix, Table S2 and Dataset S3) and
recovered 14-3-3 proteins as well as another well-characterized
LRRK2 interactor, STUB1/CHIP (17). This experiment also
yielded several additional candidates, including two candidates
that are in risk loci for sporadic PD: Rab7L1 (5, 6) and GAK
(7, 8). Because of our interest in the genetic basis of PD, we
chose to consider Rab7L1 (RAB7, member RAS oncogene
family-like 1) and Cyclin-G–associated kinase (GAK) in sub-
sequent experiments.
We first validated individual interactions between LRRK2
and each candidate. Flag-tagged BAG5 coimmunoprecipitated
endogenous LRRK2 (Fig. 1B), and reciprocally, endogenous
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BAG5 coimmunoprecipitated with LRRK2 in stable cell lines
(SI Appendix, Fig. S2A). Endogenous BAG5 coimmunoprecipi-
tated with endogenous LRRK2 in the mouse brain (SI Appendix,
Fig. S2B). Similarly, we found that endogenous LRRK2 coim-
munoprecipitated Flag-tagged Rab7L1 (Fig. 1C) or GFP-tagged
GAK (Fig. 1D). Collectively, these results show that LRRK2 can
interact with three candidate proteins (BAG5, Rab7L1, and
GAK), including endogenous protein in cells and the brain.
It is likely that different proteins have different sequence
requirements for binding LRRK2. For example, when 14-3-3
proteins were dissociated from LRRK2 by treating with the
LRRK2 kinase inhibitor LRRK2-IN1 (18), endogenous BAG5
remained bound (SI Appendix, Fig. S2C). To address the se-
quence requirements for BAG5-LRRK2 interactions further,
we used a DARA mutant BAG5, where key aspartate and argi-
nine residues in the BAG domains were replaced with alanine,
diminishing heat shock cognate protein 70 (Hsc70) binding (13).
DARA-BAG5 had lower binding to LRRK2 than WT BAG5 (SI
Appendix, Fig. S2D) [mean intensity of BAG5 relative to
LRRK2 (± SEM) of 0.49 ± 0.023 for WT and 0.21 ± 0.037 for
DARA; P = 0.0097, two-tailed paired t test, n = 3 independent
experiments], showing that recruitment of Hsc70/heat shock pro-
tein 70 (Hsp70) stabilizes the BAG5-LRRK2 complex.
Considering LRRK2, the C-terminal Ras of complex protein
(COR) domain was sufficient for interaction with BAG5 (SI
Appendix, Fig. S2E). LRRK1, with 46% similarity in the COR
domain to LRRK2, also interacted with BAG5 (SI Appendix, Fig.
S2F). These results show that the BAG5-Hsc70/Hsp70 complex
is recruited to the COR domain of LRRK proteins. Adding
recombinant BAG5 to LRRK2 did not affect kinase activity
(SI Appendix, Fig. S2G).
To confirm the interactions using an additional independent
technique, GST-BAG5 was used to pull down myc-LRRK2 from
cells (SI Appendix, Fig. S3A). This technique also confirmed that
the COR domain of LRRK2 was sufficient for BAG5 interaction
(SI Appendix, Fig. S3B). Therefore, the LRRK2-BAG5 inter-
actions were supported by protoarrays, coimmunoprecipitation,
and GST pull downs.
Some LRRK2 interactors are also substrates for LRRK2
(19, 20). When testing whether BAG5 was a LRRK2 substrate, we
recovered a copurifying autophosphorylated protein of ∼150 kDa
(SI Appendix, Fig. S4 A and B). Given the results in the second
protoarray experiment with full-length LRRK2, we considered
GAK (143 kDa) as a candidate for this unknown kinase. Sup-
porting this hypothesis, we found that GAK coimmunoprecipi-
tated with WT BAG5 but not DARA mutant, suggesting that
this interaction is also Hsp70-mediated (Fig. 1E). Furthermore,
endogenous BAG5 was coimmunoprecipitated with GAK in the
mouse brain (SI Appendix, Fig. S4C). Deletion of the PTEN-like
domain of GAK disrupted and expression of the PTEN-like do-
main was sufficient for interaction with both BAG5 and LRRK2
(SI Appendix, Fig. S4D).
These results do not discriminate whether BAG5 and LRRK2
bind independently to GAK or whether the three proteins are
present in a cocomplex. To address these possibilities, we per-
formed sequential coimmunoprecipitation experiments. GAK was
recovered from BAG5 purification like in the single coimmuno-
prectipitation; then, LRRK2 was coimmunprecipitated from the
GAK-BAG5 complexes (Fig. 1F). Furthermore, the cocomplex
was more easily recovered with WT than DARA BAG5, again
suggesting that Hsp70/Hsc70 stabilizes the overall assembly.
Fig. 1. A LRRK2 protein complex. (A) Ideograms of LRRK2 and candidate
protein interactors. LRRK2 shows the location of the mutations used in this
study, including pathogenic mutations (red) and T1348N or K1906M hy-
pothesis-testing mutants (black). Domains include leucine-rich repeat (LRR),
Ras of complex protein (ROC), and COR as well as kinase and WD40 domains.
The protoarray baits used in each experiment are boxed. BAG5 has five BAG
domains. GAK has PTEN-like domain (PTEN), Clathrin binding domain (CBD),
and J domain. Rab7L1 has a single Ras-like domain. (B–E) Single-protein
interactions. Coimmunoprecipitations using antibodies to (B and C) Flag or
(D) GFP from cell lysates expressing (B) BAG5, (C) Rab7L1, or (D) GAK with (B)
mock-transfected cells, (C) Flag-β-glucoronidase (GUS), or (D) GFP as nega-
tive controls probed for endogenous LRRK2 (arrows), Hsc70 (closed arrow-
head), and tagged proteins (open arrowheads). IB, immunoblotting; IP,
immunoprecipitation. (E) IP of BAG5 probed for endogenous GAK (arrow-
heads). (F and G) Cocomplex formation between LRRK2, GAK, BAG5, and
Rab7L1. (F) Lysates were immunoprecipitated first with Flag for BAG5 and
then with GFP for GAK, and they were probed for LRRK2 and interacting
partners. (G) Flag-tagged Rab7L1 complexes probed for endogenous LRRK2,
GAK, Hsc70, and Bag5. For all panels, markers on the right of the blots are
in kilodaltons, and results are representative of at least three independent
experiments.














To address whether the interactions require all components or
can be formed in the absence of any one member, we knocked
down each component in turn and performed coimmunopre-
cipitation experiments for the remaining partners. These results
(SI Appendix, Fig. S4 E–G) showed that interactions remained
even when BAG5, GAK, or LRRK2 was depleted from cells.
We next considered whether Rab7L1 might be part of the
same protein complex. Rab7L1 was coimmunoprecipitated with
LRRK2, and this binding was not significantly altered by muta-
tions in LRRK2 (SI Appendix, Fig. S5 A and B). However, de-
letion of the N-terminal HEAT [Huntingtin, elongation factor
3 (EF3), protein phosphatase 2A (PP2A), TOR1] region of
LRRK2 weakened interaction dramatically (SI Appendix, Fig. S5
C and D).
Rab7L1 is a single-domain protein, and therefore, we did not
generate truncation constructs that would likely be misfolded.
Instead, we asked whether LRRK2 interactions depended on the
nucleotide state of Rab7L1. To this end, we generated T21N and
Q67L mutants in Rab7L1 that were predicted to lack GTP
binding and show impaired GTP hydrolysis based on structural
modeling (SI Appendix, Fig. S6 A–C). As expected, T21N was
deficient in GTP binding (SI Appendix, Fig. S6D) [F(4,15), P =
4.5 × 10−13, one-way ANOVA, n = 4 independent experiments].
Unexpectedly, Q67L had an ∼10-fold higher GTP/GDP disso-
ciation rate than WT Rab7L1 (SI Appendix, Fig. S6 E and F), and
both mutants showed altered mobility on size exclusion chro-
matography (SI Appendix, Fig. S5 G and H). Therefore, both
Rab7L1 mutants act as loss-of-function variants, likely because
of failure to retain GTP. Both T21N and Q67L Rab7L1 showed
enhanced interaction with LRRK2 (SI Appendix, Fig. S6 I and J)
[one-way ANOVA; F(4,10), P = 4.71 × 10−9, n = 3 independent
experiments], suggesting that Rab7L1 binds LRRK2 in both the
GTP- and GDP-bound states. However, GTP binding seemed to
be important for some functions of Rab7L1, because both Rab7L1
mutants showed diminished (Q67L) or abolished (T21N) Golgi
localization (SI Appendix, Fig. S6K). Endogenous Rab7L1 could
simultaneously coimmunoprecipitate endogenous LRRK2, GAK,
Hsp70, and BAG5 (Fig. 1G). Collectively, these results suggest
that all five proteins are in a single complex.
We next asked whether the formation of a single-protein com-
plex implied that these proteins have similar effects in cells. We
used neurite shortening, which is exaggerated by pathogenic
LRRK2 mutations (21–24). WT BAG5 caused neurite short-
ening, but this effect was diminished with the DARA mutant
BAG5 (SI Appendix, Fig. S7 A–C) [F(2,158) = 109, P < 2 × 10−16
by one-way ANOVA; n > 140 cells across three independent
experiments]. Expression of full-length GAK, but not the de-
letion constructs incapable of binding LRRK2 (SI Appendix,
Fig. S7D) [F(3,215) = 5.97, P = 6.3 × 10−4 by one-way ANOVA;
n > 49 cells per construct across two independent experiments),
and expression of WT Rab7L1, but not the GTP binding-
deficient Q67L variant, also decreased neurite length (SI Appendix,
Fig. S7E) [F(2,435) = 55, P < 2 × 10−16 by one-way ANOVA;
n > 125 cells across three independent experiments]. The effect
of Rab7L1 was diminished in LRRK2 KO neurons (SI Appendix,
Fig. S7F) [two-way ANOVA, F(1,281) = 21, P = 0.00076 for
genotype; F(1,281) = 2.7, P = 0.06 for Rab7L1 variant; F(1,281) =
21, P = 2.04 × 10−5 for interaction; n > 70 cells counted per
Fig. 2. (A) LRRK2 complex and LRRK2 mutations promote clearance of trans-Golgi–derived vesicles. Clustering and clearance of trans-Golgi by LRRK2 and
interacting partners. Primary neurons were transfected with the indicated constructs and stained for transfection markers (green) and trans-Golgi (GLG1;
blue). Right shows higher magnification of the circled neurons, whereas adjacent cells (asterisks) show normal Golgi morphology, including clustered Golgi in
Rab7L1 (Lower Right) transfections and a LRRK2-transfected neuron with minimal residual Golgi staining (Center Right). (B) Blinded counts of cells with
normal Golgi (blue), clustered Golgi (orange), or minimal or no apparent Golgi staining (white) as a proportion of all counted cells (n > 50 cells in three
independent cultures per construct, P values are by Fisher exact test for proportions against GUS-transfected cultures corrected for the number of tests
applied). (C and D) Pathogenic mutations in LRRK2 increase clearance of the trans-Golgi network. HEK cells were transfected with indicated LRRK2 variants or
GUS as a negative control and stained with antibodies to TGN46. Counting of different Golgi phenotypes after transfections with different LRRK2 variants (C)
without or (D) with cotransfection of Rab7L1 and statistical analysis were performed as in B. (E) Minimal functional complex includes LRRK2, BAG5 GAK, and
Rab7L1. Cells were transfected with GUS (negative control for transfection), BAG5, LRRK2, GAK, or Rab7L1 and simultaneously treated with siRNA against the
other components. Counting of different Golgi phenotypes after transfections with different combinations was performed as in C and D.
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condition), suggesting that the effects of Rab7L1 require expression
of LRRK2.
We next asked where each protein might be in the cell. LRRK2
was present in microsomes as reported (25), and endogenous
BAG5 and GAK were also present in the same subcellular
fractions (SI Appendix, Fig. S8A). To provide additional resolution,
we expressed each interactor as tagged proteins in neurons, al-
lowing us to use the same antibody for visualization. LRRK2 was
cytosolic and vesicular (18, 26), and BAG5 was cytosolic and
nuclear, whereas GAK and Rab7L1 were largely vesicular (SI
Appendix, Fig. S8B). When coexpressed, LRRK2 and GAK showed
vesicular colocalization. WT Rab7L1 promoted vesicular LRRK2
localization, but the Q67L Rab7L1 variant that was deficient in
GTP binding prevented this effect (SI Appendix, Fig. S8C).
These results show that a cocomplex of these proteins may
form in vesicular compartments of the cell and that the effects
require GTP binding by Rab7L1.
To further understand the possible function of the complex,
we considered what type of vesicular compartments to which it
might localize. Both Rab7L1 (27, 28) and GAK (29, 30) are re-
ported to localize to the trans-Golgi network (TGN). WT Rab7L1
expressed alone (SI Appendix, Fig. S6K) or with LRRK2 (SI
Appendix, Fig. S9 A and B) partially colocalized with markers of
the TGN but not retromer (31) (SI Appendix, Fig. S9C). When
we coexpressed both Rab7L1 and LRRK2, TGN staining was
diminished and therefore, appeared clustered in the perinuclear
area. Quantification showed that this phenotype was stronger
for TGN (TGN46, trans-Golgi network integral membrane protein
2) than cis-Golgi (GM130, Golgin subfamily A member 2) markers
(SI Appendix, Fig. S6 A and B) [F(3,8) = 56.9, P = 9.7 × 10−6 for
TGN46; F(3,8) = 9.5, P = 0.0051 for GM130; one-way ANOVA).
These results suggest that Rab7L1 directs LRRK2 to TGN-
derived vesicles.
In LRRK2-transfected neurons, the TGN was again clus-
tered, or dramatically, only residual staining was visible (Fig. 2A).
Counting cells showed that there was a significant change in the
proportions of cells with clustered or cleared Golgi after expres-
sion of LRRK2 or each interaction partner—BAG5, Rab7L1, or
GAK (Fig. 2B, P values) (two-sided Fisher exact test corrected
for the number of tests performed). Validating these results
biochemically, HEK cells expressing LRRK2 had lower amounts
of the TGN marker TGN46 (SI Appendix, Fig. S10 A and B) (P =
0.00038, t test with Welch correction, n = 5 samples) but not the
cis-Golgi marker GM130 (SI Appendix, Fig. S10C) (P = 0.07).
Considering the timing of these events, the recruitment of LRRK2
to TGN46-positive vesicles by Rab7L1 was complete by 24 h after
transfection, but clearance of Golgi increased up to 72 h (SI
Appendix, Fig. S11). Therefore, physical recruitment of LRRK2
to the TGN precedes removal of TGN-derived vesicles.
The clearance of the TGN potentially provides a cellular mea-
sure of the function of LRRK2 and binding partners. We next
asked whether point mutations in LRRK2 affect Golgi clearance,
thus allowing us to infer what functional roles of LRRK2 are
important. All pathogenic mutations in LRRK2, including those
mutations that increase kinase activity (G2019S) or decrease GTP
turnover (R1441C and Y1699C), enhanced Golgi clearance (Fig.
2C, P values). However, hypothesis-testing mutations that di-
minish GTP binding (T1348N) or are kinase-inactive (K1906M)
did not support Golgi clearance. The effects of LRRK2 muta-
tions on Golgi clearance were enhanced by Rab7L1 (Fig. 2D,
P values). These results suggest that the known enzymatic
functions of LRRK2 (GTP binding and kinase activity) are
important in the clearance of Golgi by a LRRK2 complex.
To define the minimum functional unit of the complex, we
transfected cells with BAG5, LRRK2, GAK, or Rab7L1 and
knocked down each of the other components in turn. We found
that knockdown of any single component was able to rescue the
effects of increased expression of other components on Golgi
turnover (Fig. 2E, P values). Given that knockdown of each com-
ponent did not disrupt protein interactions (SI Appendix, Fig.
S4 E–G), these results show that, even if a complex forms, full
function requires all components.
To confirm these results in vivo, we used lentiviral vectors to
express enhanced green fluorescent protein (eGFP)-tagged G2019S
LRRK2 in the striatum of adult mice. We found more cells with
minimal staining for GLG1, a TGN marker suitable for immu-
nostaining in rodent tissue, after expression of mutant LRRK2
compared with controls (Fig. 3) [F(2,12) = 131.4, P = 6.93 ×
10−9; one-way ANOVA, n = 3 animals per group]. These results
suggest that increased expression of LRRK2 has similar func-
tional effects in the mouse brain as in cellular systems.
We next sought to understand the mechanisms involved in
TGN turnover. The above results are reminiscent of the effects
of expression and activity of another Parkinson-related protein,
Parkin, that promotes removal of mitochondria by autophagy
(32). LRRK2 has previously been reported to control autophagy
in several systems (24, 33, 34). To test whether the autophagy–
lysosome system contributed to LRRK2-dependent phenotypes,
we treated cells with bafilomycin-A1, which prevents lysosomal
acidification. Bafilomycin-A1 blocked the effect of LRRK2 (Fig.
4 A and B, P values) and also prevented the turnover of TGN46-
positive vesicles when LRRK2 was cotransfected with GAK (SI
Appendix, Fig. S12A).
Asking whether the effects were specifically related to autophagy,
we found that the effects of LRRK2 were diminished by siRNA
against the autophagy protein ATG7 (Fig. 4C). Morphologically,
cells expressing LRRK2 and treated with bafilomycin-A1 con-
tained larger LRRK2-positive structures adjacent to lysosomes (SI
Appendix, Fig. S12B). When cotransfected, both Rab7L1 and
LRRK2 were found in swollen vesicles near lysosomes (SI
Appendix, Fig. S12C). Some areas of TGN46 immunoreactivity
Fig. 3. Acute expression of mutant LRRK2 in adult mouse brain results in
diminished staining of TGN markers in vivo. (A) Mouse striatum sections
from animals 2 wk after injection with lentiviral vectors expressing either
(Left) eGFP or (Right) G2019S mutant eGFP-LRRK2 stained for GFP (green),
GLG1 (red), and TOPRO3 (blue in Bottom). (B) Counting of cells with minimal
GLG1 staining in animals transduced with the vectors, with untransduced
cells in the same sections also counted as controls. Error bars show SEM.
***P < 0.001 (Tukey posthoc test from one-way ANOVA compared with
eGFP control).














were enclosed by swollen LRRK2/Rab7L1-positive vesicles (SI
Appendix, Fig. S12D). Collectively, these results support the
hypothesis that turnover of TGN vesicles depends on the
autophagy–lysosome system.
The above results make the assumption that increasing the
expression of LRRK2 or its binding partners models the di-
rection of effect of genetic risk in PD. To evaluate whether
expression of these genes might explain the risk of PD in the
human brain, we assayed a series of postmortem samples (n ∼ 60)
using exome sequencing and RNA-Seq. We examined the loci
containing Rab7L1 (SI Appendix, Fig. S13A), GAK (SI Appendix,
Fig. S13B), or LRRK2 (SI Appendix, Fig. S13C) for sequence
variants. Although we reliably detected expression of LRRK2,
GAK, and Rab7L1 in the human cerebral cortex, many patho-
genic variants were too rare to be analyzed or in regions that did
not code for RNA. However, rs708723 in the 3′ UTR of Rab7L1
could be identified directly from RNA-Seq data (Fig. 4D). There
was lower expression of the C allele in RNA-Seq data in het-
erozygous carriers, and the proportions of C alleles in the ag-
gregate counts were significantly different between exome and
RNA-Seq data (Fig. 4E) (χ2 test, χ2 = 5.9, P = 0.015). The
C allele of rs708723 was associated with a lower risk of PD (odds
ratio = 0.914, P = 0.000554 under an additive model). Therefore,
higher expression of normal sequence variants is a plausible
mechanism for risk of PD, at least for Rab7L1.
Discussion
Here, we used an unbiased survey of protein interactions of
LRRK2 to identify binding partners and show that these proteins
form a cocomplex that promotes TGN removal by autophagy-
dependent mechanisms. TGN clearance also occurs in the brain
in vivo, and expression levels of some of the protein components
are a reasonable mechanism for risk of sporadic PD. Our results
overall lead us to propose that several PD genes act in a common
pathway (SI Appendix, Fig. S14).
Because LRRK2 has several proposed interaction domains, it
may act as a scaffold for multiple interaction partners. Although
we recovered known direct binding partners of LRRK2 (15, 35)
and inferred indirect interaction with Hsp70 (17), not all pro-
posed literature candidates were identified. This result may in-
dicate a false-negative rate with arrays, which do not include all
splice variants of all proteins in the human genome or all post-
translational modifications. The approach used here should be
combined with other methods, which has been suggested more
generally for understanding protein function (36).
With these caveats, our approach led us to show that LRRK2
promotes the relocalization to and clearance of trans-Golgi–
derived vesicles. This effect is presumably related to the known
function of LRRK2 in autophagy (18, 24, 33, 37, 38) but can be
tied mechanistically to disruption of TGN. Interestingly, auto-
phagic vesicles may derive from the trans-Golgi network (37);
hence, altered turnover of Golgi-derived vesicles would impact
autophagy function over time, consistent with effects of LRRK2
deficiency in animal models (34).
Critically, this activity is enhanced by all pathogenic mutations
in LRRK2. However, LRRK2 mutants do not alter binding to its
partner proteins. This observation suggests that the enzymatic
activity of LRRK2, including GTP binding and kinase activ-
ity, may be critical for activity of the complex. Supporting this
idea, hypothesis-testing mutations lacking GTP binding or
kinase activity do not promote clearance of the TGN-derived
structures. It is possible that, after being bound, protein in-
teraction partners also influence either LRRK2 kinase activity or
GTP affinity. Defining the stoichiometry of the complex and
effects on LRRK2 is an important future goal.
The other proteins each seem to be required for LRRK2 to
affect Golgi clearance by autophagy. We have shown that removal
of BAG5, GAK, or Rab7L1 does not prevent LRRK2 binding
with other partners, implying that formation of a partial complex
is not sufficient for Golgi clearance. Within the complex, we
speculate that each protein may play a specific role. It is of in-
terest that Rab7L1 is localized to the trans-Golgi network, likely
in its GTP-bound form, where it might recruit LRRK2 and other
components to cooperatively cause TGN to be engulfed by the
autophagosomes. The presence of BAG5 and Hsp70/Hsc70 sug-
gests that this process requires remodeling of proteins or protein
complexes. GAK is also known to cooperate to remodel clathrin
complexes (39).
Our results have the broadest implications for mechanisms of
understanding disease risk for loci identified by GWASs. Higher
Fig. 4. Mechanism of turnover of Golgi-derived vesicles involves the
autophagy–lysosomal system and is consistent with altered gene expression
in the human brain. (A–C) Selective Golgi clearance involves the autophagy–
lysosome system. (A) Cells coexpressing LRRK2 (red) and GUS (blue) stained
for TGN46 (green) after treatment for 24 h with DMSO or 10 nM bafilomycin
A1. A cell with only residual TGN46 is shown in Right. (B and C) Blinded
counts of the proportions of Golgi phenotypes in cells treated with (B)
bafilomycin A1 or (C) knockdown of Atg7. (D and E) Gene expression in the
human brain. (D) Direct assay of rs708723 in Rab7L1 from the brain of an
individual who was heterozygous at this marker using RNA-Seq. (E) Density
plots for the proportion of reads with the C allele for RNA-Seq (red) and
exome data for DNA (blue) in brains from individuals heterozygous for
rs708723. There is departure from the expected proportion of 0.5 (black
vertical line) for RNA-Seq data.
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expression of Rab7L1 is associated with higher risk of PD
in humans, expression quantitative trait locus identified by
microarrays, thus providing a reasonable mechanism for the
action of the WT allele. We cannot exclude that other genes at
each GWAS locus may contribute to disease risk, because sev-
eral of these loci are complex genetically (9). However, identi-
fication of GAK and Rab7L1 as binding partners of LRRK2
from an unbiased screen raises the probability that these genes
explain some of the GWAS signal. This concept has important
implications for other diseases that have been studied by
GWASs, because it supports the idea that integrating datasets
from multiple unbiased approaches leads to unexpected insights
into human diseases.
Materials and Methods
Detailed materials and methods are included in SI Appendix. Briefly, iden-
tification of protein interactors was achieved by screening two batches of
Protoarrays (Invitrogen) with either truncated GST-LRRK2970–2527 (Invitrogen)
or full-length protein prepared as described (16). Protein interactions were
validated using coimmunoprecipitation in HEK293FT cells or mouse brain
and also GST pull downs in cells or brain. Subcellular fractionation was
performed as described (25) using LRRK2-transfected HEK293FT cells. Protein
localization and effects on turnover of TGN were performed using primary
postnatal cortical neurons with calcium–phosphate transfection (40) or in
HEK293FT cells. All counting experiments were performed by an operator
blinded to the transfection construct used; details of blinding and statistical
approaches are included in SI Appendix.
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